Quantcast

Latest Novo Nordisk Stories

2014-06-24 16:26:05

University of Copenhagen This is the first time that researchers have analysed big data relating to an entire country's disease development. The new ground-breaking results are based on data from 6.2 million Danes who were followed for 14.9 years – using state-of-the-art systems biology, researchers have boiled down the massive amount of data to 1,171 so-called thoroughfares with central information on the course of diabetes, chronic obstructive pulmonary disease, cancer, arthritis and...

2014-06-20 23:06:47

ResearchMoz.us includes new market research report "Insulin Delivery Devices Market to 2019 - Simplified Pump Solutions and Low Cost Pens Represent Distinct Regional Growth Drivers" to its huge collection of research reports. Albany, NY (PRWEB) June 20, 2014 The report provides comprehensive information on the key trends affecting these segments, and key analytical content on the market dynamics. The report also reviews the competitive landscape, analyzes each segment’s...

2014-06-20 23:06:12

Market Size - $1,326.6 Mn 2013, Market Growth - CAGR of 16.2%, Market Trends –Innovations such as ultra-long acting analogs new report by Grand View Research. View full report with TOC - http://www.grandviewresearch.com/industry-analysis/latin-merica-insulin-market. San Francisco, California (PRWEB) June 20, 2014 The Latin America market for Insulin is expected to reach USD 3,760.7 million by 2020, according to a new study by Grand View Research, Inc. Growing prevalence of diabetes...

2014-06-19 08:30:01

Latest delivery device advancement in the basal insulin category PLAINSBORO, N.J., June 19, 2014 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced the availability of its newest prefilled insulin delivery device Levemir(®) FlexTouch(®) (insulin detemir [rDNA origin] injection) in the United States. This device represents an advancement in insulin delivery and is based on years of feedback from endocrinologists, certified diabetes educators, primary care...

2014-06-18 23:12:11

Global Type 1 Diabetes Market 2014-2018 a research report available at ReportsnReports.com. Dallas, Texas (PRWEB) June 18, 2014 The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key...

2014-06-18 16:27:04

The Diabetes Advocacy Alliance(TM) Urges Congress to Pass the National Diabetes Clinical Care Commission Act This Congressional Session WASHINGTON, June 18, 2014 /PRNewswire-USNewswire/ -- In light of startling new data from the Center for Disease Control and Prevention's (CDC) National Diabetes Statistics Report, 2014, which show the relentless rise of diabetes and prediabetes in America, the Diabetes Advocacy Alliance(TM) (DAA) urges Congress to pass the National Diabetes Clinical...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...

2014-06-06 08:25:22

Diabetes leader nominated by Plainsboro's Mayor Peter Cantu PLAINSBORO, N.J., June 6, 2014 /PRNewswire/ -- Novo Nordisk, a global health care company with more than 90 years of innovation and leadership in diabetes care, will be presented today with a 2014 New Good Neighbor Award for its new LEED Silver certified US headquarters in Plainsboro, New Jersey. The company was given this award based on a variety of factors, including economic benefit/job creation, architectural merit, and...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related